7801-71-0

Basic information

• Product Name: Z-LEU-LEU-OH
• Synonyms: N-CARBOBENZOXY-L-LEUCYL-L-LEUCINE;Z-LEU-LEU-OH;Z-L-LEUCYL-L-LEUCINE;CBZ-L-LEU-L-LEU;N-[N-(benzyloxycarbonyl)-L-leucyl]-L-leucine;Cbz-L-Leu-L-Leu-OH;Z-L-Leu-L-Leu-OH;(S)-2-((S)-2-(((Benzyloxy)carbonyl)aMino)-4-MethylpentanaMido)-4-Methylpentanoic acid
• CAS NO: 7801-71-0
• Molecular Formula: C₂₀H₃₀N₂O₅
• Molecular Weight: 378.46
• EINECS: 232-258-7
• Mol File: 7801-71-0.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 598°Cat760mmHg
• Flash Point: 315.5°C
• Appearance: /
• Density: 1.13g/cm³
• Vapor Pressure: 3.77E-15mmHg at 25°C
• Refractive Index: 1.52
• Storage Temp.: -15°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Z-LEU-LEU-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-LEU-LEU-OH(7801-71-0)
• EPA Substance Registry System: Z-LEU-LEU-OH(7801-71-0)

Safety Data

• Hazardous Substances Data: 7801-71-0(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C20H30N2O5/c1-13(2)10-16(18(23)21-17(19(24)25)11-14(3)4)22-20(26)27-12-15-8-6-5-7-9-15/h5-9,13-14,16-17H,10-12H2,1-4H3,(H,21,23)(H,22,26)(H,24,25)

Upstream product

• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 2018-66-8 Z-Leu-OH 
• 2666-93-5 (S)-Leu-OMe 
• 51021-87-5 N-benzyloxycarbonyl-L-leucine methyl ester 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 40162-58-1 Z-Leu-Leu-OtBu 
• 7797-39-9 Z-L-Leucin-<5-chlor-chinolyl-(8)-ester> 
• 61-90-5 L-leucine 
• 71800-39-0 N-benzyloxycarbonylated amide of L-leucylleucine 
• 64187-29-7 Z-L-Leu-OCH₂CN 
• 3397-35-1 Z-L-leucine hydroxysuccinimide ester 
• 3504-37-8 Cbz-L-Leu-L-Leu-OMe 

Downstream Products

• 106561-18-6 N-(benzyloxycarbonyl)-L-leucyl-L-leucyl-L-leucine methyl ester 
• 98695-41-1 N-carbobenzoxy-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucine methyl ester 
• 1384458-03-0 N-(N-benzyloxycarbonyl-L-leucyl-L-leucyl)-2-(diethoxyphosphoryl)glycine methyl ester 
• 1384458-04-1 (Z)-N-(N-benzyloxycarbonyl-L-leucyl-L-leucyl)-α,β-dehydro-5-(phenyl)norvaline methyl ester 
• 1402348-91-7 N-(N-benzyloxycarbonyl-L-leucyl-L-leucyl)-L-threonine methyl ester 
• 133407-82-6 N-(benzyloxycarbonyl)-leucinylleucinylleucinal 
• 1374568-54-3 benzyl (S)-1-{(S)-1-[(S)-1,1-diiodo-5-methyl-2-oxohexan-3-yl-amino]-4-methyl-1-oxopentan-2-ylamino}-4-methyl-1-oxopentan-2-ylcarbamate 
• 1211877-22-3 ((S)-1-(((S)-1-(((S)-1-hydroxy-4-methylpentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester 
• 227184-97-6 1-(4-isobutyl-5-oxo-4,5-dihydro-oxazol-2-yl)-3-methyl-butyl-carbamic acid benzyl ester 
• 186961-85-3 (S)-4-[(S)-2-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-3-oxo-5-phenyl-2-(triphenyl-λ⁵-phosphanylidene)-pentanoic acid benzyl ester 

Relevant articles and documents

Application of proteasome inhibitor in inhibition of novel coronavirus

The invention provides application of a proteasome inhibitor in inhibition of a novel coronavirus or preparation of novel coronavirus inhibitors. The proteasome inhibitor has a structure represented by a formula (I) or isomers, pharmaceutically acceptable salts thereof and prodrugs thereof. According to the application, by applying the proteasome inhibitor to inhibition of the novel coronavirus, good inhibiting activity is obtained, and a novel treatment way of think is provided for diseases such as pneumonia caused by the novel coronavirus.

A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities

Inhibitors of the proteasome have been extensively studied for their applications in the treatment of human diseases such as hematologic malignancies, autoimmune disorders, and viral infections. Many of the proteasome inhibitors reported in the literature target the non-primed site of proteasome's substrate binding pocket. In this study, we designed, synthesized and characterized a series of novel α-keto phenylamide derivatives aimed at both the primed and non-primed sites of the proteasome. In these derivatives, different substituted phenyl groups at the head group targeting the primed site were incorporated in order to investigate their structure-activity relationship and optimize the potency of α-keto phenylamides. In addition, the biological effects of modifications at the cap moiety, P1, P2 and P3 side chain positions were explored. Many derivatives displayed highly potent biological activities in proteasome inhibition and anticancer activity against a panel of six cancer cell lines, which were further rationalized by molecular modeling analyses. Furthermore, a representative α-ketoamide derivative was tested and found to be active in inhibiting the cellular infection of SARS-CoV-2 which causes the COVID-19 pandemic. These results demonstrate that this new class of α-ketoamide derivatives are potent anticancer agents and provide experimental evidence of the anti-SARS-CoV-2 effect by one of them, thus suggesting a possible new lead to develop antiviral therapeutics for COVID-19.

Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors

On the basis of the application of proline-boronic acid as pharmacophore in the kinase inhibitors and our previous research results, using proline-boronic acid as warhead, two series of peptide proline-boronic acids, dipeptide proline-boronic acids (I) and tripeptide proline-boronic acids (II), were designed and synthesized. All the synthesized compounds were first evaluated for their biological activity against MGC803 cell, and then, the best compound II-7 was selected to test its anti-tumor spectrum on six human tumor cell lines and proteasome inhibition against three subunits. The results indicated that series II have much better biological activities than series I. The compound II-7 exhibited not only excellent biological activities with IC50 values of nM level in both cell and proteasome models, but also much better subunit selectivity. Thus, proline-boronic acid as warhead is reasonable in the design of proteasome inhibitors.